RESEARCH ARTICLE

REVISED Nucleocytoplasmic distribution of S6K1 depends on the density and motility of MCF-7 cells *in vitro* [version 2; peer review: 2 approved]

Viktoriia Kosach ¹, Kateryna Shkarina^{1,2}, Anastasiia Kravchenko², Yuliia Tereshchenko², Evelina Kovalchuk³, Larysa Skoroda³, Mykhailo Krotevych³, Antonina Khoruzhenko ¹

¹Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, Kyiv, 03143, Ukraine

²Educational and Scientific Center, Taras Shevchenko National University of Kyiv, Kyiv, 03022, Ukraine

³National Cancer Institute, Kyiv, 03022, Ukraine

v2 First published: 23 Aug 2018, 7:1332
<https://doi.org/10.12688/f1000research.15447.1>
 Latest published: 17 Dec 2018, 7:1332
<https://doi.org/10.12688/f1000research.15447.2>

Abstract

Background: The ribosomal protein S6 kinase 1 (S6K1) is one of the main components of the mTOR/S6K signal transduction pathway, which controls cellular metabolism, autophagy, growth, and proliferation. Overexpression of S6K1 was detected in tumors of different origin including breast cancer, and correlated with the worse disease outcome. In addition, significant accumulation of S6K1 was found in the nuclei of breast carcinoma cells suggesting the implication of kinase nuclear substrates in tumor progression. However, this aspect of S6K1 functioning is still poorly understood. The main aim of the present work was to study the subcellular localization of S6K1 in breast cancer cells with the focus on cell migration.

Methods: Multicellular spheroids of MCF-7 cells were generated using agarose-coated Petri dishes. Cell migration was induced by spheroids seeding onto adhesive growth surface and subsequent cultivation for 24 to 72 hours. The subcellular localization of S6K1 was studied in human normal breast and cancer tissue samples, 2D and 3D MCF-7 cell cultures using immunofluorescence analysis and confocal microscopy.

Results: Analysis of histological sections of human breast tissue samples revealed predominantly nuclear localization of S6K1 in breast malignant cells and its mainly cytoplasmic localization in conditionally normal cells. *In vitro* studies of MCF-7 cells demonstrated that the subcellular localization of S6K1 depends on the cell density in the monolayer culture. S6K1 relocation from the cytoplasm into the nucleus was detected in MCF-7 cells migrating from multicellular spheroids onto growth surface. Immunofluorescence analysis of S6K1

Open Peer Review

Approval Status

	1	2
version 2 (revision) 17 Dec 2018		 view
version 1 23 Aug 2018	 view	 ?

1. **Olivier E. Pardo** , Imperial College
London, London, UK
2. **Yegor Vassetzky** , University of Paris-Sud
(University of Paris XI), Villejuif, France
Svetlana Dokudovskaya, UMR 8126, Institut
Gustave Roussy (IGR), University of Paris-Sud
(University of Paris XI), Villejuif, France

Any reports and responses or comments on the article can be found at the end of the article.

and immunoprecipitation assay revealed the colocalization and interaction between S6K1 and transcription factor TBR2 (T-box brain protein 2) in MCF-7 cells.

Conclusions: Subcellular localization of S6K1 depends on the density and locomotor activity of the MCF-7 cells.

Keywords

S6K1, subcellular localization, mTOR/S6K1 signaling pathway, breast cancer, TBR2, Eomesodermin, MCF-7 cell line

Corresponding author: Antonina Khoruzhenko (a.i.khoruzhenko@imbg.org.ua)

Author roles: **Kosach V:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Shkarina K:** Conceptualization, Investigation, Methodology; **Kravchenko A:** Investigation; **Tereshchenko Y:** Investigation; **Kovalchuk E:** Investigation; **Skoroda L:** Investigation; **Krotevych M:** Investigation; **Khoruzhenko A:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by National Academy of Sciences of Ukraine grants (0115U003745) and (0115U001403 to A.Khoruzhenko).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Kosach V *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Kosach V, Shkarina K, Kravchenko A *et al.* **Nucleocytoplasmic distribution of S6K1 depends on the density and motility of MCF-7 cells *in vitro* [version 2; peer review: 2 approved]** F1000Research 2018, 7:1332 <https://doi.org/10.12688/f1000research.15447.2>

First published: 23 Aug 2018, 7:1332 <https://doi.org/10.12688/f1000research.15447.1>

REVISED Amendments from Version 1

In version 2 of the manuscript we have modified the abstract and conclusions to more accurately represent the obtained data. Particularly, we have removed the statement about possible phosphorylation of transcription factor TBR2 by kinase S6K1, as it was predicted only by bioinformatic analysis. However, the existence of TBR2-S6K1 protein complex was shown by co-immunoprecipitation and colocalization assays for the first time, that is why we have left this finding in the abstract.

Information about the supplier of antibodies, that were not represented in the main figures and results (against transcription factors ERG and CDX-2), has been moved to the legend of Dataset 4.

We have removed the first introductory paragraph of the Results section, because of the feedback of both reviewers. The paragraph was descriptive, and no information about results of the research was lost.

The style and language of the manuscript was greatly improved in version 2. Some accidental typographical errors were corrected in the new version.

An additional affiliation has been listed for Kateryna Shkarina who, although was a Masters student at the Educational and Scientific Center, Taras Shevchenko National University of Kyiv at the time of version 1, carried out almost all the research at The Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine.

See referee reports

Introduction

Ribosomal protein S6 kinase 1 (S6K1) belongs to the AGC family of serine/threonine protein kinases (Ruvinsky & Meyuhas, 2006). It is involved in the regulation of crucial physiological processes, such as protein synthesis, ribosomal biogenesis, the G1/S-phase cell cycle transition, mRNA splicing, differentiation of specific cell types, and apoptosis. The large number of intracellular targets makes S6K1 a key regulator of cell size, growth, and proliferation (Magnuson *et al.*, 2012). S6K1 activity is controlled by the PI3K/Akt/mTOR signaling pathway, which has been shown to be dysregulated in diverse human pathologies, including diabetes, obesity, neurodegenerative disorders, and cancer (Tavares *et al.*, 2015). Overexpression of S6K1 was found in several tumor types, including breast cancer, and was associated with the worse disease outcome for the patients (Bostner *et al.*, 2015).

In mammalian cells, S6K1 is encoded by *RPS6KB1* gene located at the chromosome 17. Several isoforms of the S6K1 protein are known: the 85kDa S6K1 and the 70kDa S6K1 (p85S6K1 and p70S6K1 respectively), which originate from alternative translation initiation sites, and hypothetical p60S6K1, which is also suggested to be a product of alternate mRNA translation (Kim *et al.*, 2009). Recently, the new 31kDa isoform of S6K1 (p31S6K1) encoded by mRNA splice variant was also identified. Although it has been shown that p31S6K1 protein lacks the catalytic activity of the kinase domain, it still possesses oncogenic properties (Ben-Hur *et al.*, 2013; Song & Richard, 2015). The longer isoform p85S6K1 has an additional 23 amino acid extension at the N-terminus of the molecule functioning as a nuclear localization signal. In early studies p85S6K1 was

described as a predominantly nuclear localized kinase. However, recent studies based on nuclear-cytoplasmic fractionation revealed its presence in the cytoplasm of the breast cancer cells and primary human fibroblasts (Kim *et al.*, 2009; Rosner & Hengstschläger, 2011). The most abundant isoform of S6 kinase, p70S6K1, was thought to localize predominantly in the cytoplasm, however treatment of the cells with leptomycin B (the nuclear export inhibitor) has been shown to cause its accumulation in the nucleus, leading to the conclusion that p70S6K1 may shuttle between the cytoplasm and nucleus of the cell (Panasyuk *et al.*, 2006). To date, there is still very little evidence about the subcellular localization of p31S6K1. It is proposed to be present in the nuclei of human normal fibroblasts (Rosner & Hengstschläger, 2011). Overall, S6K1 subcellular localization data have been based predominantly on subcellular fractionation assay or immunocytochemical analysis of recombinantly expressed proteins. However, information about the nucleocytoplasmic distribution of the endogenous S6K1 is still limited, and mechanisms of its regulation remain elusive.

Recent studies suggest that S6K1 subcellular localization and activation may also depend on the physiological status of different tissues. Immunohistochemical analysis of malignant breast tumors revealed prominent S6K1 accumulation in the nuclei of carcinoma cells (Filonenko, 2013; Filonenko *et al.*, 2004; Lyzogubov *et al.*, 2005). In other studies, it was shown that nuclear accumulation of S6K1 correlated with the reduced tamoxifen effect in breast cancer patients, while cytoplasmic localization of S6K1 was associated with better prognosis for the patients (Bostner *et al.*, 2015).

Migration of the cancer cells is an important stage of cancer progression, leading the tumor invasion and formation of distant metastases. The recent data suggest that S6K1 may be involved in the regulation of the motility of normal and malignant cells, as knockdown of p70S6K1 or inhibition of S6K1 kinase activity caused a significant decrease in the migration speed of the prostate, breast, and ovarian cancer cells *in vitro* (Amaral *et al.*, 2016; Ip *et al.*, 2011). Moreover, activation of p70S6K1 in human ovarian carcinoma cells in response to stimulation by hepatocyte growth factor (HGF) also led to increased expression of matrix metalloproteinase 9 (MMP9) and higher migration rate of these cells (Zhou & Wong, 2006). It was shown that active p70S6K1 could also induce activation of Cdc42, Rac1, and PAK1 – the known regulators of cell migration through actin cytoskeleton remodelling (Aslan *et al.*, 2011; Liu *et al.*, 2010). Besides, S6K1 was also found to colocalize with the actin arches at the leading edge of moving mesothelioma cells. Treatment with rapamycin (specific mTOR inhibitor) reduced the formation of actin arches even when cells were stimulated with epithelial growth factor (EGF) (Berven *et al.*, 2004; Liu *et al.*, 2008). However, the link between subcellular localization of S6K1 and its functions in migrating cancer cells is not fully yet understood.

In the present research, we focused on the study of subcellular localization of endogenous S6K1 in breast tumor and normal tissue, and in breast adenocarcinoma MCF-7 cells in monolayer culture, 3D multicellular spheroids, and in the course of

induced cancer cell migration. We found that nucleocytoplasmic distribution of S6K1 depends greatly on the density of the monolayer culture, and is different between the cells in 3D vs 2D culture conditions. Moreover, we found that S6K1 is relocalized to the nucleus during migration of MCF-7 cells from multicellular spheroids onto growth surface. In addition, we analyzed the possible interaction of S6K1 with a number of transcription factors, involved in the regulation of cell motility. For the first time, we described the interaction of S6K1 and TBR2 (T-box brain protein 2) in breast cancer cell line MCF-7. Together, these data suggest that during cell migration S6K1 interacts with the transcription factors in the cell nucleus, leading to the possibility of its transcriptional regulation of the genes that are involved in the control of cellular locomotor activity.

Methods

Cell culture

Human breast adenocarcinoma cell line MCF-7 was obtained from Bank of Cell Lines of the R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU (Ukraine). The cells were cultivated in DMEM culture medium (Gibco, USA) supplemented with 10% fetal calf serum (FCS, HyClone, USA), 4 mM glutamine, 50 units/ml penicillin, 50 µg/ml streptomycin at 37°C in presence of 5% CO₂. The medium was exchanged every third day. For immunofluorescence analysis cells were seeded onto sterile glass coverslips 48 hours before the experiments.

To form multicellular spheroids, MCF-7 cells were trypsinized, and 1×10⁶ cells were seeded into 100 mm Petri dishes, that were previously coated with 1% agarose (Sigma-Aldrich, A9045), and left to form the multicellular aggregates for the additional 72 h.

For the induction of spheroid-to-monolayer transition and cell migration, multicellular spheroids were transferred onto growth surface (glass coverslip) and further cultured for 24 to 72 h. Then outspreaded spheroids were fixed and used for immunofluorescence analysis.

Cellular and spheroid morphology was also evaluated using transmitted light microscopy (CETI Versus inverted microscope, CETI, Belgium, and Leica DM 1000, Leica Microsystems, Germany).

Immunofluorescence analysis

MCF-7 cells were fixed with 10% formalin for 15 min at room temperature (RT). After this, the cells were permeabilized with 0.2% Triton X-100 in PBS for 10 min. To reduce autofluorescence, the samples were incubated with 10 mM cupric sulphate and 50 mM ammonium acetate, pH 5.0 for 30 min at RT. Non-specific binding was blocked through the incubation with 10% FCS in PBS for 30 min at 37°C in a humidified chamber.

S6K1 subcellular localization was revealed using anti-S6K1-C-terminus rabbit polyclonal antibodies (generated and evaluated

earlier (Savinska *et al.*, 2001; if you are interested in obtaining this antibody, please contact the corresponding author)) at 1:100, and anti-phospho-S6K1 (T389) rabbit polyclonal antibodies at 1:20 (Cell Signaling Technology Cat# 9205, RRID:AB_330944). The secondary Fluorescein (FITC)-AffiniPure Goat Anti-Rabbit IgG (H+L) antibody 1:400 (Jackson ImmunoResearch Labs Cat# 111-095-003, RRID:AB_2337972) were applied for 45 min at 37°C in a humidified chamber.

Double immunofluorescence analysis was performed by addition of the primary antibody mix: anti-S6K1-C-terminal mouse monoclonal antibodies (generated earlier (Pogrebnoy *et al.*, 1999); if you are interested in obtaining this antibody, please contact the corresponding author) at 1:100 + anti-TBR2 rabbit polyclonal antibodies at 1:100 (Abcam Cat# ab23345, RRID:AB_778267) overnight at +4°C in a humidified chamber. The secondary Fluorescein (FITC)-AffiniPure Donkey Anti Mouse IgG (H+L) antibody (Jackson ImmunoResearch Labs Cat# 715-095-150, RRID:AB_2340792) at 1:400, and Rhodamine (TRITC)-AffiniPure Donkey Anti-Rabbit IgG (H+L) antibody (Jackson ImmunoResearch Labs Cat# 711-025-152, RRID:AB_2340588) at 1:400 were applied for 45 min at 37°C in a humidifying chamber. Samples were embedded into Mowiol medium (Sigma-Aldrich, USA) containing 2.5% DABCO (Sigma-Aldrich), 0.5 % DAPI (Sigma-Aldrich).

Microscopy image acquisition was performed using Leica DM 1000 epifluorescent microscope and Zeiss LSM 510 META point scanning confocal microscope (Carl Zeiss Microscopy GmbH, Germany). Fluorescence images were analyzed using Fiji/ImageJ v1.52b (Fiji, RRID:SCR_002285; Schindelin *et al.*, 2012). Figures were generated with the FigureJ plugin (Mutterer & Zinck, 2013) in Fiji/ImageJ v1.52b.

For quantitative characterization of colocalization Pearson coefficient and Manders coefficients (M1 and M2) analysis was performed on the background-subtracted images using JACoP plugin (Bolte & Cordelières, 2006) in Fiji/ImageJ v1.52b. Pearson coefficient (Rr) and Manders coefficients (M1 and M2) were expressed as mean value +/-SD, the experiments were performed in duplicates. To validate and describe the obtained degree of colocalization pre-defined image sets from [Colocalization Benchmark Source](#) were used. Obtained values of the colocalization coefficients were used to find the closest benchmark.

Immunohistochemical analysis

Histological samples of human mixed ductal/lobular carcinoma of the breast and surrounding conditionally normal tissue were obtained from 10 patients within the framework of the cooperation agreement between the National Cancer Institute and the Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine. This study has been approved by the Committee on Biological & Medical Ethics of the National Cancer Institute of Ukraine (approval number - № 67, 25.03.2015). Written informed consent was obtained from all patients for the use of their tissues in research.

Sections of human breast cancer and surrounding tissues or multicellular spheroids were deparaffinized in xylene and rehydrated in a series of graded alcohol solutions. For the antigen retrieval, slides were placed in citrate buffer (10 mM citric acid, pH 6.0) and subsequently boiled two times for 5–7 min. Then, sections were treated with 0.2% Triton X-100 for 10 min. Endogenous peroxidase was quenched by incubation of the samples with the 3% H₂O₂ in PBS for 30 min. After blocking of non-specific staining with 10% FCS in PBS, sections were incubated with anti-S6K1-C-terminal rabbit polyclonal antibodies (1:100) overnight at +4°C, and next with the peroxidase-conjugated secondary antibodies (1:100; Promega Cat# W4011, RRID:AB_430833) for 1 hour at 37°C. The reaction was developed with 3,3'-diaminobenzidine (Sigma-Aldrich) solution.

Bioinformatic analysis

Prediction of potential TBR2 phosphorylation sites by S6K1 was performed using Group-based Prediction System v2.1 (Xue *et al.*, 2011; GPS, RRID:SCR_016374). The sequence of human TBR2 was obtained from the National Center for Biotechnology Information, NCBI Reference Sequence: [NP_001265111.1](#).

Immunoprecipitation and immunoblot analysis

Anti-S6K1 mouse monoclonal antibodies (Pogrebnoy *et al.*, 1999) were immobilized on protein A/G PLUS Agarose beads (Santa Cruz Biotechnology) overnight at +4°C.

MCF-7 cells were washed with ice-cold PBS and extracted with lysis buffer, containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 50 mM sodium fluoride, 5 mM β-glycerophosphate, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate and a mixture of protease inhibitors (Roche Molecular Diagnostics, France). Cell lysates were centrifuged at 13 000 rpm for 20 min at 4°C. Endogenous S6K1 was precipitated by adding 1000 μg of total cell lysates to the immobilized antibodies and incubating overnight at 4°C. Immune complexes were washed three times with lysis buffer, boiled for 5 min in Laemmli sample buffer, and used for immunoblot analysis. As a control, protein A/G PLUS Agarose beads were incubated with monoclonal antibodies or cell lysates alone.

For the western blot analysis, obtained samples were separated by 10% SDS-PAGE and transferred onto PVDF membrane (Millipore, Billerica, MA). The non-specific binding was blocked with 5% skim milk in PBST (140 mM NaCl, 2.6 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, 0.05% Tween-20, pH 7.4) for 1 h at RT, and then incubated with anti-TBR2/Eomes rabbit antibodies at 1:500 (Abcam Cat# ab23345, RRID:AB_778267) or anti-S6K1 C-terminal rabbit polyclonal antibodies 1:3000 overnight at 4°C. After washing three times with PBST, HRP-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Labs Cat# 111-035-144, RRID:AB_2307391) in 1:10 000 dilution were incubated with the membrane for 1 h at RT. The signal was developed using an enhanced chemiluminescence system (Fluoro) and then exposed to Agfa X-ray film.

Results and discussion

Immunochemical detection of S6K1 subcellular localization in human breast cancer cells

Firstly, the subcellular distribution of S6K1 was determined in the histological sections of human breast cancer and normal tissues. As in previous studies, we also observed the preferential nuclear localization of S6K1 in the malignant breast cells (Bostner *et al.*, 2015; Filonenko *et al.*, 2004) and mainly cytoplasmic one in conditionally normal adjustment tissues (Figure 1A, B).

In recent years, the 3D cell culture systems have been shown to provide numerous advantages to study tumor growth in a more physiologically relevant environment (Bingel *et al.*, 2017). This motivated us to further compare the intracellular distribution of S6K1 in MCF7 cells grown as either multicellular spheroids or a conventional monolayer cell culture. In the multicellular spheroids of MCF7 cells, we detected a strong accumulation of S6K1 in the cytoplasm and its reduction in the nuclei (Figure 1C). In contrast to this, in the 40–60% confluent monolayer of MCF7 cells S6K1 was localized mostly to the nucleus, with the moderate signal in the cytoplasm of the same cells (Figure 1D).

Nucleocytoplasmic redistribution of S6K1 in MCF-7 cells at different cell density

A significant difference in S6K1 localization in monolayer and spheroid cultures can be caused by differences in cell growth conditions in two different types of culture. Such differences could be potentially caused by a cascade of intracellular signaling events induced by cell-matrix adhesion or intercellular interactions. One may assume that the S6K1 could be involved in such intracellular rearrangement. To clarify this, we analyzed the S6K1 subcellular localization in MCF-7 cells cultured at different densities. The immunofluorescence analysis revealed the changes of S6K1 localization from the nucleus to the cytoplasm correlating with increased cell culture density (Figure 2A–E). At the lowest cell density level, S6K1 was observed predominantly in the nuclei of cultured cells whereas at the highest cell density S6K1 was concentrated in the cytoplasm.

In order to further assess the possible connection between the subcellular localization of S6K1 and the cell density, we utilized the following approach. After reaching approximately 90% of confluence, the monolayer of MCF-7 cells was gently detached from growth surface by short treatment with trypsin (w/o EDTA), and placed in fresh culture medium. Subsequent cultivation of these monolayer fragments for additional 48 h led to still high cell density in the center of fragments and decreased density of cells at the edges of the fragments. Immunofluorescence analysis of this heterogeneous population of the cells revealed that cell spreading at the edges of the dense fragments was accompanied by the alterations in S6K1 localization from predominantly cytoplasmic to nuclear (Figure 2F).

Dataset 1. Unedited images that were used in Figure 1 and Figure 2, showing S6K1 subcellular localization in breast normal tissue, cancer tissue, and in MCF-7 cells monolayer

<https://dx.doi.org/10.5256/f1000research.15447.d214430>

Figure 1. S6K1 subcellular localization in breast cancer cells *in vivo* and *in vitro*. (A) Immunohistochemical detection of S6K1 in human conditionally normal breast tissue. Magnification 400x. (B) Immunohistochemical analysis of subcellular distribution of S6K1 in human breast cancer tissue. Magnification 400x. Arrows indicate the staining in the nuclei of the cells. (C) Immunohistochemical detection of S6K1 in fixed MCF-7 multicellular spheroids. Magnification 200x. (D) Immunofluorescence image of S6K1 subcellular distribution (green) in 40% confluent MCF-7 cell monolayer. Arrows indicate the S6K1 localization in the nuclei of the cells. DNA was counterstained with DAPI (blue). Scale bars correspond to 20 μ m. The data are representative of three independent experiments.

Figure 2. S6K1 relocates from the nucleus to the cytoplasm during formation of the confluent monolayer of MCF-7 cells. MCF-7 cells were seeded onto glass coverslips in the density 10 000 cells/well (A), 30 000 cells/well (B), 50 000 cells/well (C), 70 000 cells/well (D), 100 000 cells/well (E), and cultivated for 48 hours. Then cells were fixed and stained with anti-S6K1 antibody (green). White arrows indicate the S6K1 localization in the nuclei of the cells, yellow arrows indicate the decreased staining in the nuclei. Scale bars are 20 μ m. The images are representative of three independent experiments. (F) MCF-7 cells were cultured to form a super-confluent monolayer. Then fragments of the monolayer were gently detached by short incubation with trypsin, transferred on the coverslip and left for 48 hours to grow. After this the fragments were fixed and stained with anti-S6K1 antibody (green). White arrows indicate the positive reaction in the nuclei of the cells at the leading edge of the monolayer fragment; yellow arrows indicate the decreased staining in the nuclei of the cells at the center of the monolayer fragment. Magnification 400x.

Subcellular localization of S6K1 in migrating MCF-7 cells

Obtained data led to the hypothesis that there is a possible relation between the initiation of cell migration and the relocalization of S6K1. Among the variety of cell migration models, the approaches based on the 3D cell cultures are the ones that provide several unique advantages for studying tumor cell migration and invasion (Metzger *et al.*, 2017). As mentioned previously, many studies describe the structural and physiological similarity of multicellular spheroid organization to the structure of solid malignant tumors (Rodrigues *et al.*, 2018). Also, the transformation of 3D multicellular spheroids into the 2D cell colonies upon contact with adhesive surface can be realized only through cell migration, in contrast to the monolayer migration assays, where cell proliferation also plays a role. Therefore, spheroid to monolayer reversion model to assess the nucleocytoplasmic distribution of S6K1 was utilized (Figure 3). We applied the immunofluorescence analysis of cultured cells 24 and 72 hours after initiation of the MCF7 spheroid migration. Obtained data suggested that there is a significant relocalization of S6K1 from the cytoplasm into the nuclei in course of cell migration (Figure 4A, B). The cells, remaining within the spheroid retained the positive cytoplasmic and negative nuclear reaction for S6K1, similar to the cells of spheroid at histological sections regardless of their remoteness from the edge of the spheroid (Figure 1C), while the migrating cells at the edge of the spreading spheroid demonstrated strong accumulation of S6K1 in the nuclei (Figure 4B).

Dataset 2. Unedited images from Figure 3

<https://dx.doi.org/10.5256/f1000research.15447.d214431>

The mTOR dependent Thr389 phosphorylation of S6K1 is the most frequently used marker for the S6K1 activity (Romanelli *et al.*, 2002). Therefore, we analyzed the phosphorylation status of S6K1 in MCF-7 cells during spheroid transformation into

monolayer by immunofluorescence analysis. Overall, the pattern of phospho-S6K1 distribution was similar to that observed for total S6K1 (Figure 5). In particular, in the central part of the spheroid, S6K1 was mainly observed in the cytoplasm (however some of the nuclei were positive), whereas the cells at the leading edge of spheroid demonstrated predominant nuclear localization of phospho-S6K1 (Figure 5A). Also, strong nuclear localization of phospho-S6K1 (Thr389) was revealed in monolayer culture of MCF-7 cells (Figure 5B).

Dataset 3. Unedited images that were used in Figure 4 and Figure 5, showing S6K1 and phospho-S6K1 (T389) subcellular localization during MCF-7 cell migration

<https://dx.doi.org/10.5256/f1000research.15447.d214432>

S6K1 function in nuclei and cell migration

While our data suggested that activation of cell locomotor function is accompanied by cytoplasm/nuclear shuttling of S6K1, the biological meaning of the event was not clear. One of the possible explanations could be the implication of S6K1 in the regulation of transcription factors affecting expression of genes that control cell migration.

That's why, we analyzed the subcellular distribution of several transcription factors, which are known to be regulated by the mTOR/S6K signaling pathway and activated in migrating cells either in the cancer tissues or in the process of embryonic development. One of them is the mammalian transcription factor CDX2, which plays a key role in intestinal development and differentiation. It has been previously described that reduced expression of CDX2 may contribute to the colon tumorigenesis through involvement in the mTOR-mediated chromosomal instability (Aoki *et al.*, 2003). Fusion of another transcription factor ERG and androgen-responsive TMPRSS2 serine protease has been shown to contribute to the development of the

Figure 3. Scheme of the multicellular spheroid formation and initiation of cell migration. To generate multicellular spheroids, MCF-7 cells were seeded in the Petri dishes precoated with 1% agarose, and cultivated for 72 hours. To analyze cell migration, obtained spheroids were transferred onto glass coverslips and cultured for 24 or 72 hours. Transmitted light images of the spheroids general view were taken by Leica DM1000 (Leica, Germany). Magnification 200x.

Figure 4. S6K1 shuttles to the nuclei during spheroid-to-monolayer reversion. (A) Immunofluorescence analysis of S6K1 subcellular localization (green) in the MCF-7 spheroid reversed for 24 hours. Arrows indicate predominantly nuclear distribution of the S6K1 in the migrating cells. DNA was counterstained with DAPI (blue). Scale bars correspond to 20 μ m. (B) Immunofluorescence analysis of S6K1 subcellular localization (green) in the MCF-7 cells at the leading age of spheroid reversed for 72 hours. Arrows point to predominantly nuclear distribution of the S6K1 in the migrating cells. DNA was counterstained with DAPI (blue). Scale bars correspond to 20 μ m. The images are representative of three independent experiments.

Figure 5. Immunofluorescence analysis of phospho-S6K1 (T389) subcellular localization. (A) Confocal image of MCF-7 cells in spheroid-to-monolayer reversion model. Cells were stained with anti-phospho-S6K1 (T389) (green). DNA was counterstained with DAPI (blue). Scale bars correspond to 20 μ m. Arrows indicate the staining in the nuclei of the migrating cells at the leading edge of the spheroid. (B) Confocal image of monolayer culture of the MCF-7 cells stained with anti-phospho-S6K1 antibody (T389) (green). DNA was counterstained with DAPI (blue). Scale bars correspond to 20 μ m. The images are representative of two independent experiments.

prostate cancer. There is also a strong correlation between TMPRSS2-ERG fusion and activation of mTOR/S6K pathway (Faraj *et al.*, 2013; King *et al.*, 2009). The third transcription factor chosen for this study was T-box transcription activator Eomesodermin (or TBR2) (Conlon *et al.*, 2001), which was also described as one of the targets for anticancer therapy. It has been shown that siRNA knockdown of Eomesodermin in human hepatocellular carcinoma could significantly decrease anchorage-independent cell growth (Gao *et al.*, 2014). Besides this, TBR2 has also been shown to be involved in the process of lymphocyte differentiation. The mTOR-dependent regulation of expression of transcription factors T-bet and Eomesodermin has been shown to be heavily involved in the determination of effector of memory cell fates in CD8+ T cells (Cui *et al.*, 2016).

Our immunofluorescence analysis of subcellular distribution of S6K1 and mentioned transcription factors in MCF-7 cells revealed that ERG was present in scant quantities or not determined at all in MCF-7 cells (Dataset 4; (Kosach *et al.*, 2018d)). CDX2 staining led to identification of positive dots predominantly in the nuclei of the MCF7 cells, however, CDX-2 and S6K1 colocalization was not detectable by confocal microscopy (Dataset 4; (Kosach *et al.*, 2018d)). TBR2/Eomesodermin positive speckles were observed in the cytoplasm as well as in nuclei of the cells (Figure 6A, B). In both cases, partial but intense colocalization of TBR2 and S6K1 was detected. Moreover, in the low-density monolayer, when S6K1 localized mainly in the cell nuclei, TBR2 was observed predominantly in the nuclei as well. In the high-density monolayer cultures, where S6K1 was distributed in the cell cytoplasm, TBR2 also displayed a similar pattern of intracellular distribution (Figure 6A, B).

Dataset 4. Unedited images of S6K1 colocalization with transcription factors TBR2 (Figure 6), ERG (Dako, Cat#M7314), and CDX2 (Abcam Cat# ab76541, RRID:AB_1523334)

<https://dx.doi.org/10.5256/f1000research.15447.d214433>

For quantitative characterization of S6K1 and TBR2 colocalization, Pearson coefficient (Rr) and Manders coefficient (M1 and M2) analysis was performed on background-subtracted images using JACoP ImageJ plugin (Bolte & Cordelières, 2006). M1 shown the colocalization of S6K1 with TBR2, whereas M2 expressed the pool of TBR2 colocalizing with S6K1. Colocalization analysis of S6K1 and TBR2 in low density monolayer revealed Pearson coefficient $Rr = 0.55 \pm 0.113$, $M1 = 0.999 \pm 0.01$, $M2 = 0.84 \pm 0.087$. To validate and describe the obtained degree of colocalization pre-defined image sets from Colocalization Benchmark Source were used. The closest benchmark was CBS007RGM that corresponded to 60% colocalization, thus indicating the medium level of colocalization between TBR2 and S6K1. A slightly lower but reliable colocalization of S6K1 and TBR2 was observed in a monolayer with a high density. Namely Pearson coefficient was $Rr = 0.47 \pm 0.064$, Manders coefficients were $M1 = 0.995 \pm 0.004$ and $M2 = 0.62 \pm 0.187$. So, a slightly higher level of S6K1 and TBR2 colocalization was revealed in MCF-7 cells grown in low density monolayer, when S6K1 and TBR2 localized mainly in the nuclei.

Further immunoprecipitation experiments also confirmed the physical interaction of S6K1 and TBR2 (Figure 7). Protein complexes containing S6K1 were extracted from cultured MCF-7 cell lysate using anti-S6K1 antibodies and then blotted

Figure 6. S6K1 partially colocalizes with transcription factor TBR2 in MCF-7 cells. (A) Immunofluorescence image of low density monolayer culture of the MCF-7 cells co-stained with anti-S6K1 (green) and anti-TBR2 (magenta) antibodies. DNA was counterstained with DAPI (blue). Scale bars correspond to 20 μ m. Arrows indicate the regions of S6K1 and TBR2 colocalization. (B) Immunofluorescence image of high density monolayer culture of the MCF-7 cells double stained with anti-S6K1 (green) and anti-TBR2 (magenta) antibodies. DNA was counterstained with DAPI (blue). Scale bars correspond to 20 μ m. Arrows point out to the regions of S6K1 and TBR2 colocalization. The images are representative of two independent experiments.

with antibodies to TBR2. Obtained results revealed the protein complex formation of S6K1 and TBR2, leading to the hypothesis of the possibility of TBR2 regulation via S6K1 mediated phosphorylation.

Dataset 5. Unedited western blot images of co-immunoprecipitation of S6K1 and TBR2 used in Figure 7

<https://dx.doi.org/10.5256/f1000research.15447.d214434>

To assess this possibility of S6K1-mediated TBR2 phosphorylation, we performed a computational prediction of phosphorylation sites in TBR2 (GPS 2.1), which indicated several potential phosphorylation sites, and three of them (Thr421, Thr423,

Ser646) could be phosphorylated by S6K1 with a high probability score (Figure 8). Interestingly, both Thr421 and Thr423 were located in the DNA binding domain indicating that their phosphorylation could be related to the binding affinity of this transcription factor to the DNA. Another phosphorylation site (Ser646) was located within transcription activation domain at C-terminus of TBR2, which is thought to be involved in transcription activation. Taken together, this data suggests that S6K1 can be involved in the regulation of TBR2 transcription activity. However, further research is needed to confirm if S6K1 phosphorylates TBR2 *in vitro* and *in vivo*.

In the course of embryonic and postnatal development, Eomesodermin has been shown to induce the expression of a large

Figure 7. Co-Immunoprecipitation of S6K1 and TBR2 protein complex in the MCF-7 cells. Endogenous S6K1 was precipitated with anti-S6K1 mouse monoclonal antibodies immobilized on protein A/G PLUS Agarose beads (Santa Cruz Biotechnology). As a control, protein agarose beads were incubated with monoclonal antibodies or cell lysates alone. Immune complexes were analyzed by immunoblotting with anti-TBR2 rabbit antibodies (Abcam, ab23345) or anti-S6K1 C-terminal rabbit polyclonal antibodies. The data are representative of two independent experiments.

Figure 8. S6K1 possibly phosphorylates TBR2 at several residues. Group-based Prediction System v2.1 was used for bioinformatics analysis. It revealed that TBR2 contained three sites that could be phosphorylated by S6K1 with a high probability (A). Two of them, Thr421 and Thr423, are located in the DNA binding domain of the TBR2. Third site Ser646 is located within the transcription activation domain at C-terminus of TBR2 (B).

spectrum of mesodermal genes in all types of mesodermal cells, which could also be expressed in malignant cells of non-mesodermal origin (Reim *et al.*, 2017; Russ *et al.*, 2000).

Considering the multiplicity of S6K1 substrates, possible phosphorylation of the TBR2 transcription factor is not the only reason for the movement of the kinase from the cytoplasm into the nucleus of migrating cells. However, the proposed interaction can partially explain the accumulation of kinase in the nucleus of moving cells. In addition to the previously known classical nuclear substrates of S6K1, in case of breast cancer, it is necessary to note that this kinase can activate estrogen receptor- α , which is a nuclear transcription factor by its phosphorylation at Ser167 in a ligand-independent manner (Yamnik & Holz, 2010). Besides, recent data indicate that S6K1 is targeted by histone acetyltransferases p300 and p300/CBP-associated factor (PCAF). The significance of this acetylation is not fully clear, but by analogy with S6K2, it is assumed that S6K1 is involved in the regulation of the transcription process (Fenton *et al.*, 2010). Summing up, there are a number of data confirming the nuclear localization of S6K1, but the role that S6K1 performs in the nucleus of migrating malignant cells require further investigation.

Conclusions

For the first time, this study revealed the interconnection between MCF-7 cell density and S6K1 subcellular distribution: nuclear localization of the kinase was observed at low density monolayer, while in the confluent monolayer S6K1 was detected predominantly in the cytoplasm. Besides, S6K1 nucleocytoplasmic relocation was revealed in migrating MCF-7 cells using spheroid-to-monolayer reversion model.

Data availability

F1000Research: Dataset 1. Unedited images that were used in Figure 1 and Figure 2, showing S6K1 subcellular localization in

breast normal tissue, cancer tissue, and in MCF-7 cells monolayer. 10.5256/f1000research.15447.d214430 (Kosach *et al.*, 2018a).

F1000Research: Dataset 2. Unedited images from Figure 3, 10.5256/f1000research.15447.d214431 (Kosach *et al.*, 2018b).

F1000Research: Dataset 3. Unedited images that were used in Figure 4 and Figure 5, showing S6K1 and phospho-S6K1 (T389) subcellular localization during MCF-7 cell migration. 10.5256/f1000research.15447.d214432 (Kosach *et al.*, 2018c).

F1000Research: Dataset 4. Unedited images of S6K1 colocalization with transcription factors TBR2 (Figure 6), ERG, and CDX2. 10.5256/f1000research.15447.d214433 (Kosach *et al.*, 2018d).

F1000Research: Dataset 5. Unedited western blot images of co-immunoprecipitation of S6K1 and TBR2 used in Figure 7. 10.5256/f1000research.15447.d214434 (Kosach *et al.*, 2018e).

Grant information

This work was supported by National Academy of Sciences of Ukraine grants (0115U003745) and (0115U001403 to A.Khoruzhenko).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

We would like to thank Prof. Valeriy Filonenko for support, expertise, and discussions that greatly assisted the research. We also thank Dr. Volodymyr Shablii for antibodies against transcription factors (TBR2, CDX2, ERG), and Dr. Serhiy Karakhim for help in obtaining the confocal images at Light Microscopy Facility of the O.V. Palladin Institute of Biochemistry of NAS of Ukraine.

References

- Amaral CL, Freitas LB, Tamura RE, *et al.*: **S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.** *BMC Cancer*. 2016; **16**: 602.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Aoki K, Tamai Y, Horiike S, *et al.*: **Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc^{Δ716} Cdx2^{-/-} compound mutant mice.** *Nat Genet*. 2003; **35**(4): 323–330.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Aslan JE, Tormoen GW, Loren CP, *et al.*: **S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation.** *Blood*. 2011; **118**(11): 3129–3136.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ben-Hur V, Denichenko P, Siegfried Z, *et al.*: **S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1.** *Cell Rep*. 2013; **3**(1): 103–115.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Berven LA, Willard FS, Crouch MF: **Role of the p70^{S6K} pathway in regulating the actin cytoskeleton and cell migration.** *Exp Cell Res*. 2004; **296**(2): 183–195.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bingel C, Koeneke E, Ridinger J, *et al.*: **Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance.** *Cell Death Dis*. 2017; **8**(8): e3013.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bolte S, Cordelières FP: **A guided tour into subcellular colocalization analysis in light microscopy.** *J Microsc*. 2006; **224**(Pt 3): 213–232.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bostner J, Karlsson E, Eding CB, *et al.*: **S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.** *Endocr Relat Cancer*. 2015; **22**(3): 331–343.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Conlon FL, Fairclough L, Price BM, *et al.*: **Determinants of T box protein specificity.** *Development*. 2001; **128**(19): 3749–3758.
[PubMed Abstract](#)
- Cui N, Su LX, Wang H, *et al.*: **mTOR Modulates Lymphocyte Differentiation through T-bet and Eomesodermin in Response to Invasive Pulmonary Aspergillosis in Rats.** *Chin Med J (Engl)*. 2016; **129**(14): 1704–1710.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Faraj SF, Albadine R, Chaux A, *et al.*: **Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.** *Urology*. 2013; **82**(5): 1083–1089.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fenton TR, Gwaller J, Ericsson J, *et al.*: **Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases in vitro and in vivo.** *Int J Biochem Cell Biol*. 2010; **42**(2): 359–366.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Filonenko VV: **PI3K/mTOR/S6K signaling pathway - new players and new**

functional links. *Biopolym Cell.* 2013; **29**(3): 207–214.

[Publisher Full Text](#)

Filonenko VV, Tytarenko R, Azatjan SK, *et al.*: Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors. *Exp Oncol.* 2004; **26**(4): 294–299.

[PubMed Abstract](#)

Gao F, Xia Y, Wang J, *et al.*: Integrated analyses of DNA methylation and hydroxymethylation reveal tumor suppressive roles of *ECM1*, *ATF5*, and *EOMES* in human hepatocellular carcinoma. *Genome Biol.* 2014; **15**(12): 533. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Ip CK, Cheung AN, Ngan HY, *et al.*: p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. *Oncogene.* 2011; **30**(21): 2420–2432.

[PubMed Abstract](#) | [Publisher Full Text](#)

Kim D, Akcakanat A, Singh G, *et al.*: Regulation and localization of ribosomal protein S6 kinase 1 isoforms. *Growth Factors.* 2009; **27**(1): 12–21.

[PubMed Abstract](#) | [Publisher Full Text](#)

King JC, Xu J, Wongvipat J, *et al.*: Cooperativity of *TMPRSS2-ERG* with PI3-kinase pathway activation in prostate oncogenesis. *Nat Genet.* 2009; **41**(5): 524–526.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Kosach V, Shkarina K, Kravchenko A, *et al.*: Dataset 1 in: Nucleocytoplasmic distribution of S6K1 depends on the density and motility of MCF-7 cells *in vitro*. *F1000Research.* 2018a.

<http://www.doi.org/10.5256/f1000research.15447.d214430>

Kosach V, Shkarina K, Kravchenko A, *et al.*: Dataset 2 in: Nucleocytoplasmic distribution of S6K1 depends on the density and motility of MCF-7 cells *in vitro*. *F1000Research.* 2018b.

<http://www.doi.org/10.5256/f1000research.15447.d214431>

Kosach V, Shkarina K, Kravchenko A, *et al.*: Dataset 3 in: Nucleocytoplasmic distribution of S6K1 depends on the density and motility of MCF-7 cells *in vitro*. *F1000Research.* 2018c.

<http://www.doi.org/10.5256/f1000research.15447.d214432>

Kosach V, Shkarina K, Kravchenko A, *et al.*: Dataset 4 in: Nucleocytoplasmic distribution of S6K1 depends on the density and motility of MCF-7 cells *in vitro*. *F1000Research.* 2018d.

<http://www.doi.org/10.5256/f1000research.15447.d214433>

Kosach V, Shkarina K, Kravchenko A, *et al.*: Dataset 5 in: Nucleocytoplasmic distribution of S6K1 depends on the density and motility of MCF-7 cells *in vitro*. *F1000Research.* 2018e.

<http://www.doi.org/10.5256/f1000research.15447.d214434>

Liu L, Chen L, Chung J, *et al.*: Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. *Oncogene.* 2008; **27**(37): 4998–5010.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Liu L, Luo Y, Chen L, *et al.*: Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. *J Biol Chem.* 2010; **285**(49): 38362–38373.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Lyzogubov V, Khozhaenko Y, Usenko V, *et al.*: Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer. *Exp Oncol.* 2005; **27**(2): 141–144.

[PubMed Abstract](#)

Magnuson B, Ekim B, Fingar DC: Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. *Biochem J.* 2012; **441**(1): 1–21.

[PubMed Abstract](#) | [Publisher Full Text](#)

Metzger W, Rother S, Pohlemann T, *et al.*: Evaluation of cell-surface interaction using a 3D spheroid cell culture model on artificial extracellular matrices.

Mater Sci Eng C Mater Biol Appl. 2017; **73**: 310–318.

[PubMed Abstract](#) | [Publisher Full Text](#)

Mutterer J, Zinck E: Quick-and-clean article figures with FigureJ. *J Microsc.* 2013; **252**(1): 89–91.

[PubMed Abstract](#) | [Publisher Full Text](#)

Panasjuk G, Nemazany I, Zhyvoloup A, *et al.*: Nuclear export of S6K1 II is regulated by protein kinase CK2 phosphorylation at Ser-17. *J Biol Chem.* 2006; **281**(42): 31188–31201.

[PubMed Abstract](#) | [Publisher Full Text](#)

Pogrebnoy PV, Kukharensko AP, Tykhonkova IA, *et al.*: Generation and characterization of monoclonal antibodies to p70S6 kinase alpha. *Exp Oncol.* 1999; **21**(3–4): 232–238.

[Reference Source](#)

Reim I, Frasch M, Schaub C: T-Box Genes in *Drosophila* Mesoderm Development. *Curr Top Dev Biol.* 2017; **122**: 161–193.

[PubMed Abstract](#) | [Publisher Full Text](#)

Rodrigues T, Kundu B, Silva-Correia J, *et al.*: Emerging tumor spheroids technologies for 3D *in vitro* cancer modeling. *Pharmacol Ther.* 2018; **184**: 201–211.

[PubMed Abstract](#) | [Publisher Full Text](#)

Romanelli A, Dreisbach VC, Blenis J: Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr³⁰⁸ in p70 S6 kinase 1. *J Biol Chem.* 2002; **277**(43): 40281–40289.

[PubMed Abstract](#) | [Publisher Full Text](#)

Rosner M, Hengstschläger M: Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR. *Oncogene.* 2011; **30**(44): 4509–4522.

[PubMed Abstract](#) | [Publisher Full Text](#)

Russ AP, Wattler S, Colledge WH, *et al.*: *Eomesodermin* is required for mouse trophoblast development and mesoderm formation. *Nature.* 2000; **404**(6773): 95–99.

[PubMed Abstract](#) | [Publisher Full Text](#)

Ruvinsky I, Meyuhas O: Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. *Trends Biochem Sci.* 2006; **31**(6): 342–348.

[PubMed Abstract](#) | [Publisher Full Text](#)

Savinska LO, Kijamova RG, Pogrebnoy PV, *et al.*: Comparative characterization of S6 kinase α and β isoforms expression in mammalian tissues. *Biopolym Cell.* 2001; **17**(5): 374–379.

[Publisher Full Text](#)

Schindelin J, Arganda-Carreras I, Frise E, *et al.*: Fiji: an open-source platform for biological-image analysis. *Nat Methods.* 2012; **9**(7): 676–682.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Song J, Richard S: Sam68 Regulates S6K1 Alternative Splicing during Adipogenesis. *Mol Cell Biol.* 2015; **35**(11): 1926–1939.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Tavares MR, Pavan IC, Amaral CL, *et al.*: The S6K protein family in health and disease. *Life Sci.* 2015; **131**: 1–10.

[PubMed Abstract](#) | [Publisher Full Text](#)

Xue Y, Liu Z, Cao J, *et al.*: GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. *Protein Eng Des Sel.* 2011; **24**(3): 255–260.

[PubMed Abstract](#) | [Publisher Full Text](#)

Yamnik RL, Holz MK: mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. *FEBS Lett.* 2010; **584**(1): 124–128.

[PubMed Abstract](#) | [Publisher Full Text](#)

Zhou HY, Wong AS: Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. *Endocrinology.* 2006; **147**(5): 2557–2566.

[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 18 January 2019

<https://doi.org/10.5256/f1000research.18161.r42025>

© 2019 Vassetzky Y. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Yegor Vassetzky

French National Centre for Scientific Research(CNRS), UMR 8126, Institut Gustave Roussy (IGR), University of Paris-Sud (University of Paris XI), Villejuif, France

The authors have successfully replied to the criticism of this reviewer.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 05 October 2018

<https://doi.org/10.5256/f1000research.16834.r38191>

© 2018 Vassetzky Y et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Yegor Vassetzky

French National Centre for Scientific Research(CNRS), UMR 8126, Institut Gustave Roussy (IGR), University of Paris-Sud (University of Paris XI), Villejuif, France

Svetlana Dokudovskaya

French National Centre for Scientific Research(CNRS), UMR 8126, Institut Gustave Roussy (IGR), University of Paris-Sud (University of Paris XI), Villejuif, France

The MS by Kosach et al. describes an interesting phenomenon, nucleocytoplasmic shuttling of

S6K1 in MCF-7 cells. The authors established a relationship between MCF-7 monolayer density and subcellular localization of the kinase. The work is worthy of publication, but the MS should be significantly shortened as it contains some redundant information and speculations. Proofreading by a native English-speaker is also recommended.

Major point:

The putative phosphorylation of TBR2 by S6K1 is too speculative and not convincing to use it as one of the major conclusions of the papers. It should be either confirmed experimentally or removed from the abstract and the main results of the paper.

Minor points:

Material and Methods:

p4 Please remove "if you are interested in obtaining this antibody, please contact the corresponding author";

p4 The anti-ERG and anti-CDX antibodies are not used in the main Figures. Please move information about these antibodies from the Materials and Methods section to legends of the supplementary figures;

Results and discussion:

P5 Please remove the first paragraph or move it to the introduction section.

P5 "For the first step of the present study" is redundant

Figure 1,5 legend. Please replace "positive reaction" with "staining"

P6 The following phrase is unclear: "Since cell spreading can be considered as a stage of migration, the previous data led to the hypothesis..."

Figure 6. It is unclear whether the images represent confocal sections or reconstituted 3D images. Colocalization of S6K1 and TBR2 should be analyzed quantitatively, eg using ImageJ tools for colocalization analysis. It is also unclear whether TBR2 shuttles between the nucleus and the cytoplasm similarly to S6K1.

P9. S6K1 is a serine threonine kinase and the putative phosphorylation of TBR2 by S6K1 should concern threonines rather than tyrosines. I also propose to remove the bioinformatic part and the Figure 8 as they are too speculative. Indeed, many other kinases may potentially phosphorylate TBR2 basing on the bioinformatic analysis, and the authors did not even show whether TBR2 is indeed phosphorylated.

Figure 7. TBR2 has a molecular weight of 84 kDa of TBR2, but the major band has a lower molecular weight. This should be explained in the Results section.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response 03 Dec 2018

Viktoriia Kosach, National Academy of Sciences of Ukraine, Kyiv, Ukraine

We thank the reviewers for deep and knowledgeable revision of this manuscript. Please, find below our response to the reviewers' comments point by point.

1. *Major point: The putative phosphorylation of TBR2 by S6K1 is too speculative and not convincing to use it as one of the major conclusions of the papers. It should be either confirmed experimentally or removed from the abstract and the main results of the paper.*
We have withdrawn the mentioned statements from the conclusions and the abstract, and left as a hypothesis in the text of our article.

2. Minor points

p4 Please remove "if you are interested in obtaining this antibody, please contact the corresponding author";

We could not remove it, as this sentence is a recommendation of the F1000Research Editorial board, and it informs the other researchers, where they could obtain these antibodies to replicate the study.

p4 The anti-ERG and anti-CDX antibodies are not used in the main Figures. Please move information about these antibodies from the Materials and Methods section to legends of the supplementary figures;

We agree. We have moved mentioned information to the legend of Dataset 4.

Results and discussion:

P5 Please remove the first paragraph or move it to the introduction section.

P5 "For the first step of the present study" is redundant

Figure 1,5 legend. Please replace "positive reaction" with "staining"

P6 The following phrase is unclear: "Since cell spreading can be considered as a stage of migration, the previous data led to the hypothesis..."

We agree with all comments. We have corrected them in version 2 according to reviewers'

queries.

Figure 6. It is unclear whether the images represent confocal sections or reconstituted 3D images. Colocalization of S6K1 and TBR2 should be analyzed quantitatively, eg using ImageJ tools for colocalization analysis. It is also unclear whether TBR2 shuttles between the nucleus and the cytoplasm similarly to S6K1.

The images represent confocal sections. Colocalization of S6K1 and TBR2 was analysed using ImageJ JaCoP plugin, as it is indicated in article. As well as S6K1, we observed TBR2 nucleo/cytoplasmic relocalization that depended on cell density. Moreover, TBR2 shuttled between cytoplasm and nuclei similarly to S6K1 during spheroid to monolayer reversion. But quantitatively the level of colocalization of S6K1 and TBR2 we detected on MCF-7 monolayer at different density, because the cells are in more similar condition reliable for image analysis than in course of 3D spheroid transformation into 2D monolayer colony.

P9. S6K1 is a serine threonine kinase and the putative phosphorylation of TBR2 by S6K1 should concern threonines rather than tyrosines. I also propose to remove the bioinformatic part and the Figure 8 as they are too speculative. Indeed, many other kinases may potentially phosphorylate TBR2 basing on the bioinformatic analysis, and the authors did not even show whether TBR2 is indeed phosphorylated.

We agree that there was erratum concerning tyrosin and threonine. We have fixed it. As co-immunoprecipitation revealed the existence of S6K1-TBR2 protein complex in MCF-7 cells, we considered the theoretical probability of TBR2 phosphorylation by S6K1 kinase. Of course, this does not exclude the presence of other effectors of this transcription factor, but gives us the prerequisites for hypothesis. We removed this statement from the conclusions of the article.

Figure 7. TBR2 has a molecular weight of 84 kDa of TBR2, but the major band has a lower molecular weight. This should be explained in the Results section.

The antibody supplier also state that anti-TBR2 antibodies detects two bands in immunoblot analysis. We have found information that 4 splice isoforms of TBR2 with lower molecular weight are known today (<https://www.uniprot.org/uniprot/O95936>).

Competing Interests: No competing interests were disclosed.

Reviewer Report 28 September 2018

<https://doi.org/10.5256/f1000research.16834.r37832>

© 2018 Pardo O. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Olivier E. Pardo

Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK

The study by Kosach et al. clearly shows for the first time differential nucleo-cytoplasmic localisation of S6K1 in response to cell density and migration. It also provides some information about the type of role that S6K1 may play in the nucleus and the biological processes that may be associated.

The results shown are convincing and the quality of the data is sufficient to support the conclusions of the authors. Therefore, it is the opinion of this reviewer that the present manuscript should be accepted. However, the authors may want to address the comments below so as to improve the quality/impact of the manuscript:

1. At the end of the fourth paragraph of the Introduction, the authors refer to EGF as “endothelial growth factor”. This should be corrected to “epithelial growth factor”.
2. The value of the first paragraph of the Results section (There are several... of different function.) is not clear and should be deleted.
3. On Page 13 of the manuscript, the authors refer to 2 residues on TRB2, Tyr421 and Tyr423, as potential sites phosphorylated by S6K1. S6K2 is a Ser/Thr kinase and therefore unable to phosphorylate Tyr residues. Are the authors referring to Thr sites instead? Please clarify.
4. The authors argue that interaction of S6K1 with TRB2 may be involved in the migration of cells out of microspheres onto 2D layers. This is an interesting proposition and the manuscript would benefit from an experiment being performed using siRNAs to TRB2 and showing that this impacts either S6K1 distribution or the movement of cells out of the microspheres.
5. The style of the paper is poor in places and could be improved prior to indexing.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 03 Dec 2018

Viktoriia Kosach, National Academy of Sciences of Ukraine, Kyiv, Ukraine

We thank the reviewer for expert opinion and insightful comments on our study. We appreciate these comments, and we have tried to answer step by step. Please, find below our response to the reviewers' comments.

1. *At the end of the fourth paragraph of the Introduction, the authors refer to EGF as "endothelial growth factor". This should be corrected to "epithelial growth factor".*

We agree. It was erratum concerning EGF, and we have fixed it.

1. *The value of the first paragraph of the Results section (There are several... of different function.") is not clear and should be deleted.*

We have deleted mentioned paragraph.

1. *On Page 13 of the manuscript, the authors refer to 2 residues on TRB2, Tyr421 and Tyr423, as potential sites phosphorylated by S6K1. S6K1 is a Ser/Thr kinase and therefore unable to phosphorylate Tyr residues. Are the authors referring to Thr sites instead? Please clarify.*

Yes, of course, S6K1 is Ser/Thr protein kinase, and we wrote about Threonine 421 and Threonine 423 residues on TRB2, but, unfortunately, there was erratum in the text. We have fixed it in version 2.

1. *The authors argue that interaction of S6K1 with TRB2 may be involved in the migration of cells out of microspheres onto 2D layers. This is an interesting proposition and the manuscript would benefit from an experiment being performed using siRNAs to TRB2 and showing that this impacts either S6K1 distribution or the movement of cells out of the microspheres.*

This is a very interesting suggestion. Also, to our mind, interaction of S6K1 and TBR2 could be just one from the possible reasons of S6K1 subcellular redistribution in course of MCF-7 cell migration. The level of their colocalization is statistically significant, but not very high, so, under TBR2 down-regulation we can obtain partial alteration of S6K1 relocalization that will be difficult to assay. Therefore, in the present work, we so far only point to the revealed colocalization. And we hope to develop this area of research in future.

1. *The style of the paper is poor in places and could be improved prior to indexing.*

The manuscript was proofread by a person with advanced level of scientific English. We believe that this greatly improved the style of the text.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research